NASDAQ Companies
US-listed AI drug discovery and computational biology companies
Recursion Pharmaceuticals
AI-powered drug discovery platform. 2.4M experiments per week. Nvidia partnership. Clinical pipeline advancing.
Schrödinger
Physics-based molecular simulation. Industry-standard computational chemistry. Powers major pharma discovery.
Exscientia
AI-driven drug design. First AI-designed drugs in clinical trials. Oxford spinout with pharma partnerships.
AbCellera
AI-powered antibody discovery. Single-cell technology. Discovered bamlanivimab COVID-19 therapy.
Relay Therapeutics
Dynamo platform combining molecular dynamics with ML. Protein motion analysis for drug design.
Champions Oncology
TumorGraft platform for PDX and organoid models. Cancer translational research services.
International Exchanges
Publicly traded companies on European and Asian exchanges
Bico Group (CELLINK)
Bioprinting hardware and bioinks ecosystem. Acquired CELLINK, Dispendix, QInstruments. Stockholm listed.
BenevolentAI
Benevolent Platform for AI target discovery. AstraZeneca partnership. Amsterdam listed via SPAC.
Lonza Group
Major CDMO with primary cell and tissue culture products. Bioscience division supports drug discovery.
OTC & Smaller Caps
Companies on OTC markets and smaller exchanges
Organovo
3D bioprinting pioneer. ExVive liver and kidney tissues. Pivoted to therapeutics pipeline development.
Hepion Pharmaceuticals
NASH-focused biotech. Human liver tissue research capabilities. CRN04777 in development.
Big Pharma with NAM Investments
Major pharmaceutical companies investing in new approach methodologies
Acquired HUB Organoids. Major organoid platform investment.
Insitro partnership. Heavy AI drug discovery investment.
Aspect Biosystems partnership. Diabetes cell therapy.
$1B+ Isomorphic Labs deal. AlphaFold applications.
$1B+ Isomorphic Labs partnership. AI integration.
BenevolentAI partnership. Emulate collaboration.
Explore More
Analyze the investment landscape in human simulation technologies